- Home
- CRGX vs VINP Comparison
CRGX vs VINP Comparison
Compare CRGX & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- VINP
- Stock Information
- Founded
- CRGX 2021
- VINP 2009
- Country
- CRGX United States
- VINP Brazil
- Employees
- CRGX N/A
- VINP N/A
- Industry
- CRGX
- VINP Investment Managers
- Sector
- CRGX
- VINP Finance
- Exchange
- CRGX Nasdaq
- VINP Nasdaq
- Market Cap
- CRGX 621.4M
- VINP 641.7M
- IPO Year
- CRGX 2023
- VINP 2021
- Fundamental
- Price
- CRGX $13.84
- VINP $10.11
- Analyst Decision
- CRGX Strong Buy
- VINP Strong Buy
- Analyst Count
- CRGX 6
- VINP 2
- Target Price
- CRGX $31.80
- VINP $13.50
- AVG Volume (30 Days)
- CRGX 228.3K
- VINP 73.2K
- Earning Date
- CRGX 03-20-2025
- VINP 02-05-2025
- Dividend Yield
- CRGX N/A
- VINP 6.28%
- EPS Growth
- CRGX N/A
- VINP N/A
- EPS
- CRGX N/A
- VINP 0.60
- Revenue
- CRGX N/A
- VINP $88,217,697.00
- Revenue This Year
- CRGX N/A
- VINP $17.23
- Revenue Next Year
- CRGX N/A
- VINP $51.06
- P/E Ratio
- CRGX N/A
- VINP $16.71
- Revenue Growth
- CRGX N/A
- VINP 9.03
- 52 Week Low
- CRGX $10.91
- VINP $9.01
- 52 Week High
- CRGX $33.92
- VINP $11.85
- Technical
- Relative Strength Index (RSI)
- CRGX 49.08
- VINP 55.73
- Support Level
- CRGX $10.91
- VINP $9.61
- Resistance Level
- CRGX $15.75
- VINP $10.14
- Average True Range (ATR)
- CRGX 1.14
- VINP 0.25
- MACD
- CRGX 0.13
- VINP 0.06
- Stochastic Oscillator
- CRGX 59.55
- VINP 87.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.